home / stock / mdna:cc / mdna:cc news


MDNA:CC News and Press, Medicenna Therapeutics Corp.

Stock Information

Company Name: Medicenna Therapeutics Corp.
Stock Symbol: MDNA:CC
Market: TSXC
Website: medicenna.com

Menu

MDNA:CC MDNA:CC Quote MDNA:CC Short MDNA:CC News MDNA:CC Articles MDNA:CC Message Board
Get MDNA:CC Alerts

News, Short Squeeze, Breakout and More Instantly...

MDNA:CC - Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update

Medicenna to present updated internal and external data sets related to bizaxofusp (MDNA55) at the 7th Annual Glioblastoma Development Summit to be held in Boston from 17-19 February 2026 Updated ABILITY-1 clinical data for MDNA11 demonstrates compelling activity in earlier-line expansion coh...

MDNA:CC - Medicenna Announces Changes to Board Composition

TORONTO and HOUSTON, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announces that Mr. Richard Sutin and Mr. Angel...

MDNA:CC - Expected Canadian Company Earnings on Wednesday, February 11th, 2026

Slate Grocery REIT Class U Units (SGR.U:CA) is expected to report $0.35 for Q4 2025 Waste Connections Inc. (WCN:CA) is expected to report $1.77 for Q4 2025 Versamet Royalties Corporation (VMET:CA) is expected to report $0.12 for Q4 2025 Killam Apartment Real Estate Investment Trust (K...

MDNA:CC - Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook

Among monotherapy expansion cohorts (n=21), ORR was 50% in patients treated with MDNA11 in 2L/3L setting and 42% when MDNA11 was the next treatment post-ICI failure, showing best-in-class potential for advanced cancer patients with no treatment options Among all efficacy-evaluable monotherapy...

MDNA:CC - Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors

MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H and TMB-H cancers, in each case exceeding objective response rate (ORR) benchmarks in these difficult to treat populations ...

MDNA:CC - Medicenna Therapeutics to Host a Live Webinar with Q&A to Discuss Updated MDNA11 Clinical Data

TORONTO and HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines for the treatment of cancer as well a...

MDNA:CC - Medicenna Therapeutics Reports Second Quarter Fiscal 2026 Financial Results and Provides a Corporate Update

Updated MDNA11 Clinical Data from the ABILITY-1 Study will be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress on 10 th December, 2025 Fondazion Melanoma Onus will sponsor a new clinical trial (NEO-CYT) at up to 12 cancer centres in Italy ...

MDNA:CC - Expected Canadian Company Earnings on Thursday, November 13th, 2025

Brookfield Corporation Class A Limited Voting Shares (BN:CA) is expected to report $0.95 for Q3 2025 AtkinsRéalis Group Inc. (ATRL:CA) is expected to report $0.9 for Q3 2025 Skeena Resources Limited (SKE:CA) is expected to report $-0.08 for Q3 2025 Automotive Properties Real Esta...

MDNA:CC - Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, "NEO-CYT", in High-Risk, Surgically Resectable Stage III Melanoma

NEO-CYT is a randomized, multi-centre trial of neoadjuvant MDNA11 (before curative intent surgery) sponsored by the Fondazione Melanoma Onlus, and led by Professor Paolo A. Ascierto of the Istituto Nazionale Tumori Fondazione “G. Pascale”, a leading cancer centre in Europe T...

MDNA:CC - Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025

TORONTO and HOUSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, annou...

Next 10